Synektik S.A.
Synektik Spólka Akcyjna provides products, services, and IT solutions for surgery, diagnostic imaging, and nuclear medicine applications in Poland. The company sells medical equipment used in diagnostics and therapy, and nuclear medicine. It is also involved in development of IT solutions used in radiology, as well as research, produces, and sells radiopharmaceutical products used in diagnostics … Read more
Synektik S.A. (SNT) - Net Assets
Latest net assets as of December 2025: zł258.34 Million PLN
Based on the latest financial reports, Synektik S.A. (SNT) has net assets worth zł258.34 Million PLN as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (zł605.37 Million) and total liabilities (zł347.02 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | zł258.34 Million |
| % of Total Assets | 42.68% |
| Annual Growth Rate | 32.29% |
| 5-Year Change | 177.49% |
| 10-Year Change | 292.58% |
| Growth Volatility | 117.2 |
Synektik S.A. - Net Assets Trend (2010–2025)
This chart illustrates how Synektik S.A.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Synektik S.A. (2010–2025)
The table below shows the annual net assets of Synektik S.A. from 2010 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | zł223.54 Million | +17.64% |
| 2024-12-31 | zł190.02 Million | +41.60% |
| 2023-12-31 | zł134.20 Million | +52.77% |
| 2022-12-31 | zł87.85 Million | +9.05% |
| 2021-12-31 | zł80.56 Million | +6.00% |
| 2020-12-31 | zł76.00 Million | +8.17% |
| 2019-12-31 | zł70.25 Million | +13.34% |
| 2018-12-31 | zł61.99 Million | +0.43% |
| 2017-12-31 | zł61.72 Million | +8.39% |
| 2016-12-31 | zł56.94 Million | +0.70% |
| 2015-12-31 | zł56.55 Million | -3.06% |
| 2014-12-31 | zł58.33 Million | +4.29% |
| 2013-12-31 | zł55.93 Million | +216.52% |
| 2012-12-31 | zł17.67 Million | -3.55% |
| 2011-12-31 | zł18.32 Million | +445.45% |
| 2010-12-31 | zł3.36 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Synektik S.A.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 14107.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | zł151.12 Million | 67.60% |
| Other Components | zł72.42 Million | 32.40% |
| Total Equity | zł223.54 Million | 100.00% |
Synektik S.A. Competitors by Market Cap
The table below lists competitors of Synektik S.A. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
F.I.L.A. - Fabbrica Italiana Lapis ed Affini S.p.A
F:3S0
|
$268.19 Million |
|
SNT Motiv Co Ltd
KO:064960
|
$268.20 Million |
|
Shanghai Challenge Textile Co Ltd
SHE:002486
|
$268.24 Million |
|
Ncs Testing Technology Co Ltd
SHE:300797
|
$268.33 Million |
|
Ningbo Ocean Shipping Co. Ltd. A
SHG:601022
|
$268.04 Million |
|
Enanta Pharmaceuticals Inc
NASDAQ:ENTA
|
$268.04 Million |
|
Qudian Inc
NYSE:QD
|
$267.92 Million |
|
Tianyang Hot Mel
SHG:603330
|
$267.91 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Synektik S.A.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 190,023,971 to 223,540,181, a change of 33,516,210 (17.6%).
- Net income of 102,927,868 contributed positively to equity growth.
- Dividend payments of 70,365,314 reduced retained earnings.
- Other comprehensive income decreased equity by 16,075,380.
- Other factors increased equity by 17,029,036.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | zł102.93 Million | +46.04% |
| Dividends Paid | zł70.37 Million | -31.48% |
| Other Comprehensive Income | zł-16.08 Million | -7.19% |
| Other Changes | zł17.03 Million | +7.62% |
| Total Change | zł- | 17.64% |
Book Value vs Market Value Analysis
This analysis compares Synektik S.A.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 10.29x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 536.74x to 10.29x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2010-12-31 | zł0.50 | zł269.80 | x |
| 2011-12-31 | zł2.71 | zł269.80 | x |
| 2012-12-31 | zł2.74 | zł269.80 | x |
| 2013-12-31 | zł8.35 | zł269.80 | x |
| 2014-12-31 | zł6.85 | zł269.80 | x |
| 2015-12-31 | zł6.63 | zł269.80 | x |
| 2016-12-31 | zł6.68 | zł269.80 | x |
| 2017-12-31 | zł7.24 | zł269.80 | x |
| 2018-12-31 | zł7.27 | zł269.80 | x |
| 2019-12-31 | zł8.24 | zł269.80 | x |
| 2020-12-31 | zł8.91 | zł269.80 | x |
| 2021-12-31 | zł9.45 | zł269.80 | x |
| 2022-12-31 | zł10.30 | zł269.80 | x |
| 2023-12-31 | zł15.73 | zł269.80 | x |
| 2024-12-31 | zł22.28 | zł269.80 | x |
| 2025-12-31 | zł26.21 | zł269.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Synektik S.A. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 46.04%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 15.10%
- • Asset Turnover: 1.39x
- • Equity Multiplier: 2.19x
- Recent ROE (46.04%) is above the historical average (14.95%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2010 | 31.67% | 3.43% | 2.48x | 3.72x | zł727.78K |
| 2011 | -7.76% | -3.15% | 0.89x | 2.75x | zł-3.25 Million |
| 2012 | -3.65% | -1.05% | 1.00x | 3.48x | zł-2.41 Million |
| 2013 | 14.74% | 10.65% | 0.74x | 1.88x | zł2.65 Million |
| 2014 | 6.18% | 4.58% | 0.74x | 1.83x | zł-2.23 Million |
| 2015 | -2.24% | -1.51% | 0.80x | 1.85x | zł-6.92 Million |
| 2016 | 0.68% | 0.79% | 0.54x | 1.59x | zł-5.31 Million |
| 2017 | 6.62% | 6.49% | 0.55x | 1.87x | zł-2.09 Million |
| 2018 | 16.61% | 9.77% | 0.97x | 1.75x | zł4.09 Million |
| 2019 | 13.00% | 6.78% | 1.08x | 1.78x | zł2.11 Million |
| 2020 | 11.59% | 7.03% | 0.89x | 1.86x | zł1.21 Million |
| 2021 | 10.41% | 6.52% | 0.81x | 1.98x | zł327.94K |
| 2022 | 11.73% | 6.17% | 0.71x | 2.69x | zł1.52 Million |
| 2023 | 39.08% | 11.74% | 1.49x | 2.23x | zł39.03 Million |
| 2024 | 44.54% | 13.56% | 1.66x | 1.97x | zł65.63 Million |
| 2025 | 46.04% | 15.10% | 1.39x | 2.19x | zł80.57 Million |
Industry Comparison
This section compares Synektik S.A.'s net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $24,587,575
- Average return on equity (ROE) among peers: -199.25%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Synektik S.A. (SNT) | zł258.34 Million | 31.67% | 1.34x | $268.09 Million |
| Adiuvo Investment SA (ADV) | $7.30 Million | -237.44% | 6.75x | $685.90K |
| Braster S.A. (BRA) | $650.00K | -601.08% | 36.39x | $2.89 Million |
| Genomtec S.A. (GMT) | $7.57 Million | -144.47% | 0.24x | $14.99 Million |
| Medinice S.A (ICE) | $8.23 Million | -27.31% | 0.42x | $49.49 Million |
| Medicalg (MDG) | $99.19 Million | 14.04% | 0.03x | $34.29 Million |